-logo.png?v=20220303080937 "Institute of Oncology"){kind=logo}
Oncology Institute, Inc. (NASDAQ:TOI – Get Rating) major shareholder Havencrest Healthcare Partners sold 7,153 shares of the company’s shares in a transaction that took place on Monday, September 26th. The shares sold at an average price of $4.57 for a total value of $32,689.21. Upon completion of the sale, the insider now owns 14,688,301 shares of the company’s stock valued at approximately $67,125,535.57. The transaction was disclosed in a legal filing with the SEC, which can be accessed at this link. Major shareholders who own more than 10% of a company’s stock must disclose their transactions to the SEC.
Havencrest Healthcare Partners also recently made the following trades:
- On Thursday, September 22, Havencrest Healthcare Partners sold 13,086 shares of Oncology Institute. The shares sold at an average price of $4.25 for a total value of $55,615.50.
- On Monday, September 19, Havencrest Healthcare Partners sold 19,629 shares of Oncology Institute stock. The shares sold at an average price of $4.33 for a total value of $84,993.57.
- On Friday, September 16, Havencrest Healthcare Partners sold 200,000 shares of Oncology Institute. The shares were sold at an average price of $4.50 for a total value of $900,000.00.
- On Wednesday, September 14, Havencrest Healthcare Partners sold 37,785 shares of Oncology Institute stock. The shares sold at an average price of $4.99 for a total value of $188,547.15.
- On Monday, September 12, Havencrest Healthcare Partners sold 38,000 shares of Oncology Institute stock. The stock sold at an average price of $5.52 for a total value of $209,760.00.
- On Friday, September 9th, Havencrest Healthcare Partners sold 18,900 shares of Oncology Institute. The stock sold at an average price of $5.80 for a total value of $109,620.00.
- On Wednesday, September 7th, Havencrest Healthcare Partners sold 45,000 shares of Oncology Institute stock. The stock sold at an average price of $6.04 for a total value of $271,800.00.
- On Wednesday, August 31, Havencrest Healthcare Partners sold 25,000 shares of Oncology Institute. The stock sold at an average price of $6.36 for a total value of $159,000.00.
- On Monday, August 29, Havencrest Healthcare Partners sold 15,000 shares of Oncology Institute. The stock sold at an average price of $6.14 for a total value of $92,100.00.
- On Friday, August 26, Havencrest Healthcare Partners sold 40,000 shares of Oncology Institute. The stock sold at an average price of $6.03 for a total value of $241,200.00.
Oncology Institute shares up 10.0%
Shares of TOI stock rose $0.43 during Monday’s trading to hit $4.71. 75,629 shares of the Company were exchanged compared to an average volume of 121,168. The Oncology Institute, Inc. has a 12-month low of $3.75 and a 12-month high of $12.66. The company’s 50-day moving average price is $6.02 and its 200-day moving average price is $6.64.
The Oncology Institute (NASDAQ:TOI – Get Rating) last released its earnings results on Tuesday, August 9th. The company reported earnings per share of $0.06 for the quarter. The company had revenue of $60.92 million for the quarter. As a group, research analysts expect The Oncology Institute, Inc. to post -0.51 EPS for the year to date.
Wall Street analyst ponders
A number of brokers have recently issued reports on TOI. Guggenheim assumed coverage of the Oncology Institute in a research note on Wednesday, September 14. They assigned a “buy” rating and a price target of $7.00 on the stock. The Jefferies Financial Group issued a report on the Oncology Institute on Monday, August 15. They assigned a “buy” rating and a price target of $10.00 on the stock.
Institutional inflows and outflows
A number of institutional investors and hedge funds have recently added to or reduced their holdings in TOI. American International Group Inc. acquired a new position in Oncology Institute valued at $44,000 during the second quarter. JPMorgan Chase & Co. increased its stake in Oncology Institute by 2,410.3% in the second quarter. JPMorgan Chase & Co. now owns 10,041 shares of the company’s stock, valued at $51,000, after purchasing an additional 9,641 shares last quarter. Bank of America Corp DE acquired a new position in Oncology Institute valued at $69,000 in Q1. Rhumbline Advisers acquired a new position in Oncology Institute valued at $114,000 during the second quarter. Finally, Northern Trust Corp acquired a new $129,000 position in the Oncology Institute during the first quarter. 69.97% of the shares are owned by institutional investors and hedge funds.
Company profile of the Oncology Institute
(get rating)
Oncology Institute, Inc, an oncology company, provides medical oncology services in the United States. Services include physician services, infusion and on-site dispensaries, clinical trial services, radiation, ambulatory stem cell transplant and transfusion programs, and patient support. The Company also provides and manages clinical trial services such as: These include clinical trial administration, palliative care programs and stem cell transplant services.
See also
This instant news alert was generated by MarketBeat’s narrative science technology and financial data to provide readers with the fastest, most accurate reporting. This story was reviewed by the MarketBeat editorial team prior to publication. Please send questions or comments about this story to [email protected].
Before you consider Oncology Institute, here’s what you should hear.
MarketBeat tracks Wall Street’s best-in-class, top-performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now, before the broader market takes hold… and the Oncology Institute wasn’t on the list.
While the Oncology Institute is currently rated a “buy” by analysts, top analysts believe these five stocks are better buys.
Check out the five stocks here
